title: Correction of motion artifact in transmembrane voltage-sensitive fluorescent dye emission in hearts.
abstract: Fast voltage-sensitive dyes are widely used to image cardiac electrical activity. Typically, the emission spectrum of these fluorochromes is wavelength shifted with altered membrane potential, but the optical signals obtained also decay with time and are affected by contraction. Ratiometry reduces, but may not fully remove, these artifacts. An alternate approach has been developed in which the time decay in simultaneously acquired short- and long-wavelength signals is characterized nonparametrically and removed. Motion artifact is then identified as the time-varying signal component common to both decay-corrected signals and subtracted. Performance of this subtraction technique was compared with ratiometry for intramural optical signals acquired with a fiber-optic probe in an isolated, Langendorff-perfused pig heart preparation (n = 4) stained with di-4-ANEPPS. Perfusate concentration of 2,3-butanedione monoxime was adjusted (7.5-12.5 mM) to alter contractile activity. Short-wavelength (520-600 nm) and long-wavelength (>600 nm) signals were recorded over 8-16 cardiac cycles at 6 sites across the left ventricular free wall in sinus rhythm and during pacing. A total of 451 such data sets were acquired. Appreciable wall motion was observed in 225 cases, with motion artifact classed as moderate (less than modulation due to action potential) in 187 and substantial (more than modulation due to action potential) in 38. In all cases, subtraction performed as well as, or better than, ratiometry in removing motion artifact and decay. Action potential morphology was recovered more faithfully by subtraction than by ratiometry in 58 of 187 and 31 of 38 cases with moderate and substantial motion artifact, respectively. This novel subtraction approach may therefore provide a means of reducing the concentration of uncoupling agents used in cardiac optical mapping studies.
authors.affiliation: Bioengineering Institute, The University of Auckland, Auckland, New Zealand.
authors.forename: Dean C-S
authors.initials: DC
authors.lastname: Tai
authors.forename: Bryan J
authors.initials: BJ
authors.lastname: Caldwell
authors.forename: Ian J
authors.initials: IJ
authors.lastname: LeGrice
authors.forename: Darren A
authors.initials: DA
authors.lastname: Hooks
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Pullan
authors.forename: Bruce H
authors.initials: BH
authors.lastname: Smaill
mesh_terms: D000200:Action Potentials; D000818:Animals; D016477:Artifacts; D002863:Chromogenic Compounds / Q000494:pharmacology; D003931:Diacetyl / Q000031:analogs & derivatives* / Q000494:pharmacology; D004594:Electrophysiology; D005336:Fiber Optic Technology; D005456:Fluorescent Dyes; D006321:Heart / Q000187:drug effects / Q000502:physiology*; D066298:In Vitro Techniques; D008955:Models, Cardiovascular; D009038:Motion; D009200:Myocardial Contraction / Q000187:drug effects; D055100:Optical Fibers; D009994:Osmolar Concentration; D011726:Pyridinium Compounds; D013382:Subtraction Technique; D013552:Swine; D016277:Ventricular Function, Left
chemical_list: D002863:Chromogenic Compounds; D005456:Fluorescent Dyes; D011726:Pyridinium Compounds; C004717:diacetylmonoxime; C050019:1-(3-sulfonatopropyl)-4-(beta)(2-(di-n-butylamino)-6-naphthylvinyl)pyridinium betaine; D003931:Diacetyl